Ernexa Stock Price, News & Analysis

Ernexa Therapeutics (NASDAQ: ERNA) has announced the formation of ErnexaTX2, a wholly owned subsidiary in Texas. This strategic move is designed to support the development of ERNA-101, the company's lead program targeting ovarian cancer. The subsidiary will facilitate ongoing research collaboration with Dr. Michael Andreeff from The University of Texas MD Anderson Cancer Center, an expert in cell therapy and tumor microenvironment.

The new Texas entity will help Ernexa build infrastructure for future clinical operations, including clinical manufacturing, regulatory interactions, and site activation. The company remains on schedule for IND-enabling studies in 2025, with first-in-human trials planned for 2026.

Ernexa Therapeutics (NASDAQ: ERNA) has announced its participation in the upcoming D. Boral Capital Inaugural Global Conference, scheduled for May 14, 2025, at The Plaza Hotel in New York City. The company's President & CEO, Sanjeev Luther, will be available for one-on-one meetings with interested parties from 9:00 A.M. to 3:00 P.M. (ET). Attendees wishing to schedule meetings can contact John Perez at jperez@dboralcapital.com.

Ernexa Therapeutics presented groundbreaking data at the AACR Annual Meeting 2025 showcasing a novel stem cell therapy for ovarian cancer. The company's lead product, ERNA-101, uses engineered induced pluripotent stem cells (iPSCs) transformed into induced MSCs that secrete immune-boosting cytokines IL-7 and IL-15.

Led by Dr. Michael Andreeff from MD Anderson Cancer Center, the study demonstrated that these engineered cells effectively:

• Slowed tumor growth in ovarian cancer models
• Improved survival rates
• Increased presence of crucial immune cells (T cells, NK cells, macrophages)
• Enhanced T cell growth and multiplication
• Showed better growth and multiplication compared to traditional MSCs

This breakthrough addresses previous limitations of mesenchymal stem cells in cancer treatment, offering a more effective and scalable therapeutic approach. The results support continued development of Ernexa's cancer pipeline.

Ernexa Therapeutics (NASDAQ: ERNA) has announced new data presentation at the AACR Annual Meeting 2025 in Chicago, showcasing their lead cell therapy product ERNA-101. The study, led by Dr. Michael Andreeff from MD Anderson Cancer Center, explores a novel treatment for ovarian cancer using engineered cells that deliver therapy directly to tumors.

The technology works by secreting immune-stimulating cytokines to reshape the tumor microenvironment and enhance anti-tumor immune responses. The presentation will take place on Monday, April 28, 2025, from 2:00-5:00 pm CDT in the Immunology session, focusing on local treatments and novel delivery systems to manipulate tumor immunity.

Ernexa Therapeutics (NASDAQ: ERNA) has secured a new private placement agreement with accredited investors, raising approximately $7.25 million through the issuance of 69.3 million shares of common stock at $0.1046 per share. The funding will be executed in two phases:

- First closing on April 2, 2025: ~10.4 million shares issued for $1.1 million in gross proceeds
- Second closing pending stockholder approval at June 2, 2025 annual meeting

This financing follows a previous $5 million PIPE investment in 2024 and recent company rebranding. The funds will support Ernexa's strategic focus on developing cell therapies for advanced cancer and autoimmune disease, with emphasis on their ovarian cancer program.

Eterna Therapeutics has announced its rebranding to Ernexa Therapeutics (NASDAQ: ERNA), marking a strategic shift from a cell therapy platform to focused product development in ovarian cancer and autoimmune disease treatments. The company's technology specializes in transforming induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), which can target tumors and inflammation.

Two key products are currently in preclinical trials: ERNA-101, engineered to enhance immune response against cancer cells, specifically targeting ovarian cancer as its first indication, and ERNA-102, designed to combat inflammation and treat autoimmune disease. The company aims to address significant unmet needs, particularly in ovarian cancer treatment, where current platinum-based chemotherapy often faces resistance issues.

Eterna Therapeutics (ERNA) held its first Scientific Advisory Board meeting to advance its cell therapy pipeline, particularly focusing on induced mesenchymal stem cell (iMSC) therapy programs. The board, comprising experts including Michael Andreeff, Christopher Rohde, Blythe Sather, and Jerome B. Zeldis, reviewed the company's preclinical progress and strategic direction.

Key discussions centered on ERNA-101's positive preclinical data in ovarian cancer, including immune activation and tumor microenvironment interactions. The board aligned on advancing quality criteria, regulatory engagement, and clinical trial design. They explored potential combination therapies with CAR-T therapy and MUC16-targeting agents. Additionally, they evaluated ERNA-102's potential applications in autoimmune disease treatment.

Eterna Therapeutics (ERNA) has expanded its scientific advisory board with the addition of two experts: Dr. Jerome Zeldis and Dr. Blythe Sather. Dr. Zeldis brings extensive experience in oncology therapy development, having served as Celgene's Chief Medical Officer and held leadership positions at various pharmaceutical companies. He has published 122 peer-reviewed articles and holds 44 U.S. patents.

Dr. Sather, an immunologist specializing in genetic and epigenetic modifications, brings expertise in cell therapy and genetic medicines. Her experience includes work with CRISPR gene editing, CAR-T cell therapies, and leadership roles at companies like Juno Therapeutics and Celgene.

Both advisors will contribute to advancing ERNA-101 for solid tumors and ERNA-102 for autoimmune diseases through preclinical studies.

Eterna Therapeutics (ERNA) announced positive preclinical study results for its lead cell therapy product, ERNA-101, targeting ovarian cancer. The proof-of-concept study demonstrated significant T cell infiltration after a single dose, reduced tumor burden, and extended survival in mouse models.

ERNA-101 successfully transformed 'cold' tumors into 'hot' ones by utilizing induced pluripotent stem cells to create mesenchymal stem cells that secrete interleukins IL-7 and IL-15. The therapy showed ability to enhance immune system response against tumors while limiting systemic exposure and potential toxicity.

In the study conducted at MD Anderson Cancer Center, researchers developed an ovarian tumor model using ID8 cells. The ERNA-101 treatment group showed substantially higher T cell infiltration, reduced tumor size, and significant survival advantage compared to control groups, with no significant differences in body weight distribution indicating favorable safety profile.